180 related articles for article (PubMed ID: 36733195)
1. Glioblastoma as a Novel Drug Repositioning Target: Updated State.
Hosseinalizadeh H; Ebrahimi A; Tavakoli A; Monavari SH
Anticancer Agents Med Chem; 2023; 23(11):1253-1264. PubMed ID: 36733195
[TBL] [Abstract][Full Text] [Related]
2. Repurposing drugs for glioblastoma: From bench to bedside.
Basso J; Miranda A; Sousa J; Pais A; Vitorino C
Cancer Lett; 2018 Aug; 428():173-183. PubMed ID: 29729291
[TBL] [Abstract][Full Text] [Related]
3. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
4. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
6. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
7. Drug repurposing for the treatment of glioblastoma multiforme.
Abbruzzese C; Matteoni S; Signore M; Cardone L; Nath K; Glickson JD; Paggi MG
J Exp Clin Cancer Res; 2017 Nov; 36(1):169. PubMed ID: 29179732
[TBL] [Abstract][Full Text] [Related]
8. Drug Screening of Human GBM Spheroids in Brain Cancer Chip.
Akay M; Hite J; Avci NG; Fan Y; Akay Y; Lu G; Zhu JJ
Sci Rep; 2018 Oct; 8(1):15423. PubMed ID: 30337660
[TBL] [Abstract][Full Text] [Related]
9. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
Zhang X; Ding K; Wang J; Li X; Zhao P
Biomed Pharmacother; 2019 Jan; 109():39-46. PubMed ID: 30391707
[TBL] [Abstract][Full Text] [Related]
10. Current Development of Glioblastoma Therapeutic Agents.
Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
[TBL] [Abstract][Full Text] [Related]
11. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
13. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapeutic targets and agents for glioblastoma migrating cells.
Di C; Mattox AK; Harward S; Adamson C
Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos of a case.
Karamanakos PN; Trafalis DT; Papachristou DJ; Panteli ES; Papavasilopoulou M; Karatzas A; Kardamakis D; Nasioulas G; Marselos M
J BUON; 2017; 22(5):1227-1232. PubMed ID: 29135106
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
17. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.
Rundle-Thiele D; Head R; Cosgrove L; Martin JH
Br J Clin Pharmacol; 2016 Feb; 81(2):199-209. PubMed ID: 26374633
[TBL] [Abstract][Full Text] [Related]
18. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment.
Berro A; Assi A; Farhat M; Hatoum L; Saad JP; Mohanna R; Bechara AMA; Prince G; Hachem MCR; Zalaquett Z; Kourie HR
Crit Rev Oncol Hematol; 2024 Jun; 198():104365. PubMed ID: 38677355
[TBL] [Abstract][Full Text] [Related]
19. Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery.
Nozhat Z; Heydarzadeh S; Shahriari-Khalaji M; Wang S; Iqbal MZ; Kong X
Biomater Sci; 2023 Jun; 11(12):4094-4131. PubMed ID: 37073998
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]